Active Pharmaceutical Ingredient exhibits different crystal form. The design and characterization of this new configuration is an important research line improves by the pharmaceutical industry for the solution of problems related with the quality and developing of medicaments. Active Pharmaceutical Ingredient can exhibits different crystal form. The new polymorph shows different chemistry, conformation or supramolecular aspects and diverse physic-chemistry properties, such case, eliminate the unwanted properties pharmacokinetic. Many pharmaceutical compound used in depress and epilepsy treatment show inconveniences characteristic, mainly with the solubility and bioavailability. The present proposal research aims at to design and solid-state characterization of new crystal forms of bound drugs in the therapy of this disease. The main pharmaceutical compounds are: Oxcarbazepine, Amitriptyline, Phenobarbital, Valproic acid, Fluoxetine and Paroxetine. They will be re-crystallized to elaborate modification crystalline with appropriate pharmacokinetic properties when comparison with the pure form found in medicament. These procedures involve the choice of solvents, co-cristalizante agent, temperature, pressure for the crystallization system. Additionally, the project propose the wide characterization of new crystal using other aspects of the structural analysis such as X-ray diffraction, powder diffraction, Molecular Modeling , IR and UV spectroscopy, Differential scanning calorimetric and solubility.
News published in Agência FAPESP Newsletter about the scholarship: